Diagnostics and therapeutics for diseases associated with neuromedin u2 receptor (nmu2)

A method of screening for therapeutic agents useful in the treatment of a disease selected from hematological diseases, cardiovascular diseases, disorders of the peripheral and central nervous system, cancer, genitourinary diseases and respiratory diseases in a mammal comprising the steps of

• i) determining the activity of a NMU2 polypeptide at a certain concentration of a test compound or in the absence of said test compound,
• ii) determining the activity of said polypeptide at a different concentration of said test compound.

A method of screening for therapeutic agents useful in the treatment of a disease selected from hematological diseases, cardiovascular diseases, disorders of the peripheral and central nervous system, cancer, genitourinary diseases and respiratory diseases in a mammal comprising the steps of

• i) determining the activity of a NMU2 polypeptide at a certain concentration of a test compound,
• ii) determining the activity of a NMU2 polypeptide at the presence of a compound known to be a regulator of a NMU2 polypeptide.

A method of screening for therapeutic agents useful in the treatment of a disease selected from hematological diseases, cardiovascular diseases, disorders of the peripheral and central nervous system, cancer, genitourinary diseases and respiratory diseases in a mammal comprising the steps of

• i) contacting a test compound with a NMU2 polynucleotide,
• ii) detecting binding of said test compound to said NMU2 polynucleotide.

A method of diagnosing a disease selected from hematological diseases, cardiovascular diseases, disorders of the peripheral and central nervous system, cancer, genitourinary diseases and respiratory diseases in a mammal comprising the steps of

• i) determining the amount of a NMU2 polynucleotide in a sample taken from said mammal,
• ii) determining the amount of NMU2 polynucleotide in healthy and/or diseased mammals.

A pharmaceutical composition for the treatment of a disease selected from hematological diseases, cardiovascular diseases, disorders of the peripheral and central nervous system, cancer, genitourinary diseases and respiratory diseases in a mammal comprising a therapeutic agent which binds to a NMU2 polypeptide.

A pharmaceutical composition for the treatment of a disease selected from hematological diseases, cardiovascular diseases, disorders of the peripheral and central nervous system, cancer, genitourinary diseases and respiratory diseases in a mammal comprising a therapeutic agent which regulates the activity of a NMU2 polypeptide.

A pharmaceutical composition for the treatment of a disease selected from hematological diseases, cardiovascular diseases, disorders of the peripheral and central nervous system, cancer, genitourinary diseases and respiratory diseases in a mammal comprising a NMU2 polynucleotide.

A pharmaceutical composition for the treatment of a disease selected from hematological diseases, cardiovascular diseases, disorders of the peripheral and central nervous system, cancer, genitourinary diseases and respiratory diseases in a mammal comprising a NMU2 polypeptide.

A method for the treatment of a disease selected from hematological diseases, cardiovascular diseases, disorders of the peripheral and central nervous system, cancer, genitourinary diseases and respiratory diseases in a mammal comprising administering to a mammal an effective amount of a regulator of NMU2.

A method for the regulation of NMU2 activity in a mammal having a disease selected from hematological diseases, cardiovascular diseases, disorders of the peripheral and central nervous system, cancer, genitourinary diseases and respiratory diseases comprising administering to a mammal an effective amount of a regulator of NMU2.